Amalgamated Bank Boosts Stock Position in Encompass Health Co. (NYSE:EHC)

Amalgamated Bank boosted its stake in Encompass Health Co. (NYSE:EHC) by 0.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 48,126 shares of the company’s stock after acquiring an additional 239 shares during the quarter. Amalgamated Bank’s holdings in Encompass Health were worth $4,444,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. State Street Corp raised its stake in Encompass Health by 0.7% in the 3rd quarter. State Street Corp now owns 3,025,769 shares of the company’s stock valued at $292,410,000 after purchasing an additional 21,329 shares during the last quarter. Geode Capital Management LLC boosted its stake in Encompass Health by 1.2% during the third quarter. Geode Capital Management LLC now owns 1,673,610 shares of the company’s stock worth $161,781,000 after buying an additional 20,547 shares during the last quarter. Copeland Capital Management LLC grew its holdings in Encompass Health by 0.7% in the 4th quarter. Copeland Capital Management LLC now owns 1,293,098 shares of the company’s stock valued at $119,418,000 after buying an additional 8,548 shares in the last quarter. Point72 Asset Management L.P. increased its stake in shares of Encompass Health by 2,458.5% in the 3rd quarter. Point72 Asset Management L.P. now owns 869,104 shares of the company’s stock worth $83,990,000 after acquiring an additional 835,135 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Encompass Health by 0.4% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 769,716 shares of the company’s stock worth $71,083,000 after acquiring an additional 2,904 shares during the period. Hedge funds and other institutional investors own 97.25% of the company’s stock.

Insider Activity at Encompass Health

In other Encompass Health news, CAO Andrew L. Price sold 5,042 shares of Encompass Health stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $98.29, for a total value of $495,578.18. Following the sale, the chief accounting officer now owns 69,164 shares of the company’s stock, valued at approximately $6,798,129.56. The trade was a 6.79 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.10% of the stock is currently owned by insiders.

Encompass Health Price Performance

Shares of EHC opened at $100.11 on Friday. The firm has a fifty day moving average price of $96.42 and a 200 day moving average price of $96.29. The stock has a market cap of $10.09 billion, a PE ratio of 22.45, a price-to-earnings-growth ratio of 2.31 and a beta of 0.90. Encompass Health Co. has a 1-year low of $73.68 and a 1-year high of $104.55. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.05 and a quick ratio of 1.04.

Encompass Health (NYSE:EHC) last announced its earnings results on Thursday, February 6th. The company reported $1.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.12. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. As a group, sell-side analysts anticipate that Encompass Health Co. will post 4.8 EPS for the current year.

Encompass Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 17th. Investors of record on Tuesday, April 1st will be issued a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a dividend yield of 0.68%. The ex-dividend date of this dividend is Tuesday, April 1st. Encompass Health’s dividend payout ratio is presently 15.25%.

Analyst Upgrades and Downgrades

EHC has been the topic of a number of recent analyst reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $110.00 price objective on shares of Encompass Health in a report on Tuesday, February 11th. StockNews.com raised Encompass Health from a “hold” rating to a “buy” rating in a research report on Saturday, February 15th. KeyCorp boosted their price target on shares of Encompass Health from $117.00 to $120.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. William Blair reiterated an “outperform” rating on shares of Encompass Health in a report on Friday, February 7th. Finally, Barclays raised their price target on Encompass Health from $116.00 to $118.00 and gave the stock an “overweight” rating in a research report on Friday, February 7th. Ten analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $107.67.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.